Lisa G. Wolf
Known title: COO & CFOCIK: 0001861556
Associated companies
Transaction History
| VBIO | ▲ Buy | Option Exercise | 4 | — | 9/18/2026 | View on chart |
| VBIO | ▼ Sell | Tax Withholding | 2 | $4 | 9/18/2026 | View on chart |
| VBIO | ▲ Buy | Option Exercise | 92 | — | 6/18/2026 | View on chart |
| VBIO | ▲ Buy | Option Exercise | 92 | — | 3/18/2026 | View on chart |
| VBIO | ▲ Buy | Option Exercise | 736 | — | 12/18/2025 | View on chart |
| VBIO | ▼ Sell | Tax Withholding | 302 | $565 | 12/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Valion Bio Completes Oral Mucosal Entolimod Formulation
Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.
Valion Bio Completes Oral Mucosal Entolimod Formulation. Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.